Advanced search
Start date

New therapeutic perspectives for proliferative prostate lesions treatment: immunotherapy P-MAPA associated with block angiogenesis

Grant number: 13/10521-8
Support Opportunities:Scholarships in Brazil - Scientific Initiation
Effective date (Start): January 01, 2014
Effective date (End): December 31, 2014
Field of knowledge:Health Sciences - Medicine - Surgery
Principal Investigator:Patrick Vianna Garcia
Grantee:Alexandre Motta Mecê
Host Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil


The association between immunotherapy and antiangiogenic agents may be a promising combination in the development of treatments against prostate diseases. According to preview researches, the compost P-MAPA has a very important immunotherapy effect, and its association with the angiogenic inhibitor TNP-470 may represent a new treatment for these pathologies. How in the literature there is no such association, this study aims to characterize and compare the morphological and molecular effects of anti-angiogenic therapy associated with P-MAPA immunotherapy in the treatment of prostatic lesions chemically induced. From 25 Fischer 344 male rats, 5 will be considered as a control group and 20 will be chemically induced. Each of these rats will receive daily subcutaneous doses of 100 mg/Kg of Testosterone Cypionate and they will be treated with N-methyl-N-nitrosourea (MNU, 15 mg/Kg) inoculated in the capsule of the anterior prostate lobe (1 application on every 15 days, resulting in 2 administrations). One week after the last dose, the rats will receive subcutaneous doses of 5 mg/Kg of Testosterone cypionate, in alternating days, in a period of 120 days. Then, all the animals will be submitted to ultrasound scanning and divided in five groups with 5 animals each, which will receive the following subcutaneous treatment three times a week, for 30 days: Control Group (Group 1): 5 mL/Kg of 0.9% saline solution; MNU Group (with the prostate diseases, Group 2): the same treatment as group 1; MNU + P-MAPA Group (Group 3): 5 mg/Kg of P-MAPA; MNU+TNP-470 Group (Group 4): 15 mg/Kg of TNP-470; MNU+P-MAPA+TNP-470 Group (Group 5): 5 mg/Kg of P-MAPA and 15 mg/Kg of TNP-470. Passed 150 days of treatment, the anterior prostate of the 25 animals will be extracted for histopathological analysis, immunohistochemistry, and Western Blotting. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

Please report errors in scientific publications list by writing to: